Literature DB >> 16428467

Ovarian cancer biomarkers in urine.

Ann F Chambers1, Barbara C Vanderhyden.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16428467     DOI: 10.1158/1078-0432.CCR-05-2563

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  11 in total

1.  Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care.

Authors:  Shuqi Wang; Xiaohu Zhao; Imran Khimji; Ragip Akbas; Weiliang Qiu; Dale Edwards; Daniel W Cramer; Bin Ye; Utkan Demirci
Journal:  Lab Chip       Date:  2011-09-01       Impact factor: 6.799

Review 2.  Development and validation of a protein-based signature for the detection of ovarian cancer.

Authors:  Kyongjin Kim; Irene Visintin; Ayesha B Alvero; Gil Mor
Journal:  Clin Lab Med       Date:  2009-03       Impact factor: 1.935

3.  Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet?

Authors:  Dimitra Sasaroli; George Coukos; Nathalie Scholler
Journal:  Biomark Med       Date:  2009-06-01       Impact factor: 2.851

Review 4.  Urine proteomics: the present and future of measuring urinary protein components in disease.

Authors:  Jonathan Barratt; Peter Topham
Journal:  CMAJ       Date:  2007-08-14       Impact factor: 8.262

5.  Correlation between preoperative serum levels of five biomarkers and relationships between these biomarkers and cancer stage in epithelial overian cancer.

Authors:  Jongyun Hwang; Sunghun Na; Hyangah Lee; Dongheon Lee
Journal:  J Gynecol Oncol       Date:  2009-09-30       Impact factor: 4.401

Review 6.  Diagnostic accuracy of urine HE4 in patients with ovarian cancer: a meta-analysis.

Authors:  Meng-Meng Jia; Jie Deng; Xiao-Lin Cheng; Zhen Yan; Qing-Chun Li; Ying-Ying Xing; Dong-Mei Fan; Xiao-Yu Tian
Journal:  Oncotarget       Date:  2017-02-07

Review 7.  Integration of biosensors and drug delivery technologies for early detection and chronic management of illness.

Authors:  Mpho Ngoepe; Yahya E Choonara; Charu Tyagi; Lomas Kumar Tomar; Lisa C du Toit; Pradeep Kumar; Valence M K Ndesendo; Viness Pillay
Journal:  Sensors (Basel)       Date:  2013-06-14       Impact factor: 3.576

8.  Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopy.

Authors:  Michael Kyriakides; Nona Rama; Jasmin Sidhu; Hani Gabra; Hector C Keun; Mona El-Bahrawy
Journal:  Oncotarget       Date:  2016-02-09

9.  Correlation between lung neoplasm and serum level of osteopontin: A meta-analysis.

Authors:  Dan Li; Wang Qian; Ruo Ran Li; Jinghao Zhang; K E Li; Yanmin Wu
Journal:  Biomed Rep       Date:  2016-02-29

10.  Correlation between ovarian neoplasm and serum levels of osteopontin: a meta-analysis.

Authors:  Yue-Dong Wang; He Chen; Hui-Qiag Liu; Min Hao
Journal:  Tumour Biol       Date:  2014-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.